Patents by Inventor Boris Rusjakovski

Boris Rusjakovski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5527906
    Abstract: A new and improved process for the preparation of ceftriaxon disodium salt hemiheptahydrate of formula I ##STR1## is described, wherein 7-amino-3-{[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-as-triazin-3-yl)thio]met hyl}-3-cephem-4-carboxylic acid disodium salt is converted with a reactive 2-(2-aminothiazol-4-yl)-2-syn-metoxyimino acetic acid derivative such as 2-benzo-thiazolyl-thio ester in a water solution and in the presence of a suitable inert organic solvent such as acetone, at a temperature between 0.degree. C. and 40.degree. C. and then the desired compound is isolated in a very pure form and with a high total yield.Ceftriaxon is a cephalosporin antibiotic of the third generation for parenteral application and a valuable agent for the treatment of heavy infections.
    Type: Grant
    Filed: January 27, 1993
    Date of Patent: June 18, 1996
    Assignee: LEK, tovarna farmacevtskih in kemicnik izdelkov
    Inventors: Natasa H. Milac, Igor Langof, Boris Rusjakovski, Sandi Borisek, Darja Jereb
  • Patent number: 5079237
    Abstract: There is described a new inclusion complex of nicardipine or its hydrochloride with beta-cyclohdextrin, which is prepared by admixing nicardipine or its hydrochloride with beta-cyclodextrin in a molar ratio of the compounds 1:0.9-1.1 under stirring at a temperature from about room temperature to the boiling temperature of the reaction mixture in an aqueous or ethanolic medium, cooling the reaction mixture to 0.degree. to 5.degree. C. and isolating the desired complex.The inclusion complex of nicardipine or its hydrochloride posesses cerebrovascular-vasodilatory and coronary-vasodilatory properties, which are equally well expressed as those of nicardipine or its hydrochloride themselves, yet owing to the better solubility of the complex at a higher pH range, such as it exists e.g. in the intestinal tract, the manufacture of sustained release pharmaceutical forms is made possible, whereby a greater extent of dissolution of the active substance is provided also in the intestinal juice.
    Type: Grant
    Filed: January 18, 1989
    Date of Patent: January 7, 1992
    Assignee: Lek
    Inventors: Breda Husu, Jenny Milovac, Zdravko Kopitar, Branko Huc, Janko Zmitek, Peter Bukovec, Mirjan Zorz, Boris Rusjakovski, Polona Cvelbar, Zdenka Jerala-Strukelj, Bojan Kofler
  • Patent number: 4952565
    Abstract: A new inclusion complex of ibuproxam with beta-cyclodextrin is described, which is prepared by adding ibuproxam to a boiling aqueous solution of beta-cyclodextrin, stirring the reaction mixture at the boiling temperature, cooling to a temperature of 0.degree. C. to 5.degree. C. and isolating the title complex.The analgesic, antipyretic and antiinflammatory properties of the inclusion complex of ibuproxam with beta-cyclodextrin are equivalent to those of ibuproxam alone, but owing to its better water-solubility the complex can be more easily formulated into pharmaceutical forms.
    Type: Grant
    Filed: November 13, 1987
    Date of Patent: August 28, 1990
    Inventors: Janko Zmitek, Jenny Milovac, Zdravko Kopitar, Mirjan Zorz, Boris Rusjakovski